In order to clarify the frequency of p16 gene inactivation and its relationship with Rb expression, immunohistochemical analysis of p16 and Rb proteins was carried out on 82 paraffin-embedded sections of primary non-small cell lung cancers (NSCLCs). From immunohistochemical results, abnormal p16 exp
Inversely correlated expression of p16 and Rb protein in non-small cell lung cancers: An immunohistochemical study
β Scribed by Masahiro Sakaguchi; Yoshitaka Fujii; Hirohisa Hirabayashi; Hyung-Eun Yoon; Yosuke Komoto; Takaharu Oue; Takeshi Kusafuka; Akira Okada; Hikaru Matsuda
- Publisher
- John Wiley and Sons
- Year
- 1996
- Tongue
- French
- Weight
- 469 KB
- Volume
- 65
- Category
- Article
- ISSN
- 0020-7136
No coin nor oath required. For personal study only.
β¦ Synopsis
Cdk4-mediated phosphorylation of Rb protein is inhibited by pl6, a product of a possible tumor suppressor gene. We examined the expression of p16 and Rb protein by means of immunohistochemistry in 61 non-small cell lung cancers and have demonstrated an inverse relationship between the expression of p I 6 and Rb protein: 28/30 specimens that did not stain for p i 6 stained for Rb and 2 I /3 I p 16-positive specimens did not stain for Rb. Only I of the pl6-negative specimens had a mutation of exon 2 of the CDKN2 gene. Our results indirectly
π SIMILAR VOLUMES
The retinoblastoma protein (pRB), p16, and cyclin D1 are major components of the RB pathway, which controls the G1 checkpoint of the cell cycle. Proper regulation of this pathway is crucial for normal cell proliferation. Abnormal forms of these proteins have been found in various types of malignant
Accumulation of mutant p53 protein occurs frequently in human malignancies, including 40-60% of non-small cell lung carcinomas. The implications of such p53 over-expression, usually assessed by immunohistochemical techniques, for the prognosis of lung cancer patients remain undetermined. In this stu
## Inactivation of the Rb pathway in non-small cell lung carcinoma (NSCLC) occurs mostly through inactivation of the cyclin-dependent kinase inhibitor p16 INK4A and/or up-regulation of cyclin D1. In order to assess the frequency and the prognostic value of these abnormalities in NSCLC, immunohisto
FIGURE 1 -Survival after surgery of patients with NSCLC according to p53 expression level. Log-rank tests used for comparisons.